Biomarkers and therapeutic advances in glioblastoma multiforme

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Asia-Pacific Journal of Clinical Oncology

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/ajco.12756PMID 28840962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MiRNAs as promising biomarkers in cancer

  2019cited by this paper
• A 4-miRNA signature predicts the therapeutic outcome of glioblastoma

  2016cited by this paper
• Deciphering the role of microRNA 21 in cancer stem cells (CSCs)

  2016cited by this paper
• Temozolomide resistance in glioblastoma multiforme

  2016cited by this paper
• miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma

  2016cited by this paper
• Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

  2016cited by this paper
• Immune Evasion Strategies of Glioblastoma

  2016cited by this paper
• Circulating tumor cell is a common property of brain glioma and promotes the monitoring system

  2016cited by this paper
• TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model

  2016cited by this paper
• "Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.

  2016cited by this paper
• Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

  2016cited by this paper
• Chimeric antigen receptor T-cell therapy for solid tumors

  2016cited by this paper
• Therapeutic potential of targeting microRNA‐10b in established intracranial glioblastoma: first steps toward the clinic

  2016cited by this paper
• MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT

  2016cited by this paper
• Differential localization of glioblastoma subtype: implications on glioblastoma pathogenesis

  2016cited by this paper
• Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients

  2016cited by this paper
• Nonsurgical treatment of recurrent glioblastoma.

  2015cited by this paper
• Immunotherapeutic Advancements for Glioblastoma

  2015cited by this paper
• Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

  2015cited by this paper
• Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

  2015cited by this paper
• EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

  2015cited by this paper
• Loss of heterozygosity: what is it good for?

  2015cited by this paper
• IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

  2015cited by this paper
• p53 regulates the mevalonate pathway in human glioblastoma multiforme

  2015cited by this paper
• Decreased Expression of miR-15b in Human Gliomas Is Associated with Poor Prognosis

  2015cited by this paper
• Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas

  2015cited by this paper
• Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.

  2015cited by this paper
• Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

  2015cited by this paper
• PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment

  2014cited by this paper
• Systematic Review of Interventions to Improve the Provision of Information for Adults with Primary Brain Tumors and Their Caregivers

  2014cited by this paper
• Hematogenous dissemination of glioblastoma multiforme

  2014cited by this paper
• MicroRNAs as promising biomarkers in cancer diagnostics

  2014cited by this paper
• Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males.

  2014cited by this paper
• EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

  2014cited by this paper
• Current Vaccine Trials in Glioblastoma: A Review

  2014cited by this paper
• A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas

  2014cited by this paper
• IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.

  2014cited by this paper
• CD19-CAR Trials

  2014cited by this paper
• Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.

  2014cited by this paper
• Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.

  2014cited by this paper
• Viral and Non-Viral Gene Therapy for Glioblastoma: New Insights into theTreatment of Malignant Brain Tumors

  2013cited by this paper
• Targeting the PDGF signaling pathway in tumor treatment

  2013cited by this paper
• Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

  2013cited by this paper
• MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1

  2013cited by this paper
• miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development

  2013cited by this paper
• The Mix of Two Worlds: Non-Coding RNAs and Hormones

  2013cited by this paper
• Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death.

  2013cited by this paper
• In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

  2013cited by this paper
• PDGFRA Gain in Low-Grade Diffuse Gliomas

  2013cited by this paper
• Oncogenic effects of miR-10b in glioblastoma stem cells

  2013cited by this paper
• Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.

  2013cited by this paper
• IDH1 and IDH2 Mutations in Gliomas

  2013cited by this paper
• EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

  2013cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cited by this paper
• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  2012cited by this paper
• Circulating microRNAs involved in multiple sclerosis

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• PDGF and PDGF receptors in glioma

  2012cited by this paper
• Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Molecular biomarkers of glioblastoma: current targets and clinical implications

  2012cited by this paper
• Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

  2011cited by this paper
• Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients.

  2011cited by this paper
• Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma

  2011cited by this paper
• MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?

  2011cited by this paper
• Symptoms and problems in the end-of-life phase of high-grade glioma patients.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations

  2009cited by this paper
• IDH 1 and IDH 2 Mutations in Gliomas

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Genetically engineered T cells to target EGFRvIII expressing glioblastoma

  2009cited by this paper
• Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice

  2009cited by this paper
• Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma

  2009cited by this paper
• Gene therapy for high-grade glioma

  2008cited by this paper
• Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• miR-21-mediated tumor growth

  2007cited by this paper
• MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

  2007cited by this paper
• Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

  2006cited by this paper
• Surgery, radiotherapy and temozolomide in treating high-grade gliomas.

  2006cited by this paper
• Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

  2006cited by this paper
• Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis.

  2006cited by this paper
• Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

  2005cited by this paper
• Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

  2005cited by this paper
• Proteins and Protein Pattern Differences between Glioma Cell Lines and Glioblastoma Multiforme

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Epidemiology and etiology of gliomas

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.

  2004cited by this paper
• Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

  2003cited by this paper
• Multifaceted resistance of gliomas to temozolomide.

  2002cited by this paper
• Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

  2001cited by this paper

• Liquid Biopsy as a Diagnostic and Monitoring Tool in Glioblastoma

  2025cites this paper
• In silico prediction of GRP78-CRIPTO binding sites to improve therapeutic targeting in glioblastoma

  2025cites this paper
• Neprilysin regulates the progression of glioblastoma: an in-vitro study using siRNA mediated gene silencing and HDAC1 mediated upregulation of neprilysin in U87 MG cells

  2025cites this paper
• The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma

  2025cites this paper
• Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMTmethylated/DGKImethylated glioblastoma

  2025cites this paper
• The role of DNAJC3 in enhancing glioma progression and regulating the tumor immune microenvironment

  2025cites this paper
• Онколитический потенциал вируса гриппа в терапии глиом

  2025cites this paper
• Oncolytic potential of the influenza virus in glioma therapy

  2025cites this paper
• Modern insights of nanotheranostics in the glioblastoma: An updated review.

  2025cites this paper
• Integrating machine learning with mendelian randomization for unveiling causal gene networks in glioblastoma multiforme

  2025cites this paper
• Glioblastoma IDH-wild type: imaging independent predictors of gross total resection (GTR) using the VASARI feature set and tumoral volumetric measurements

  2025influential citation
• Empowering rapid diagnosis and treatment of glioblastoma with biofunctionalized carbon quantum dots: a review

  2025influential citation
• Recent advances in biomimetic nanodelivery systems for the treatment of glioblastoma.

  2025cites this paper
• Novel Natural Inhibitors for Glioblastoma by Targeting Epidermal Growth Factor Receptor and Phosphoinositide 3-kinase.

  2024cites this paper
• Identification of Novel Molecular and Clinical Biomarkers of Survival in Glioblastoma Multiforme Patients: A Study Based on The Cancer Genome Atlas Data

  2024cites this paper
• Analysis of transcription profiles for the identification of master regulators as the key players in glioblastoma

  2024cites this paper
• Aptamers: ushering in new hopes in targeted glioblastoma therapy

  2024cites this paper
• Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma

  2024cites this paper
• Capmatinib Use in MET-Amplified Glioblastoma

  2024cites this paper
• Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma

  2024cites this paper
• The dual role of calnexin on malignant progression and tumor microenvironment in glioma

  2024cites this paper
• A review of prognostic molecular biomarkers for glioblastoma and their clinical significance for diagnosis and treatment

  2024cites this paper
• Recent in vitro models and tissue engineering strategies to study glioblastoma

  2024cites this paper
• Unveiling the Dynamics behind Glioblastoma Multiforme Single-Cell Data Heterogeneity

  2024influential citation
• Personalized treatment using predictive biomarkers in solid organ malignancies: A review

  2024cites this paper
• An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma

  2024cites this paper
• Preliminary Analysis of Solute Carrier Family in Nucleotide Rescue Synthesis in Glioma

  2024cites this paper
• Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status

  2024cites this paper
• Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma

  2023cites this paper
• Prognostic significance of alterations in fibrinogen level and fibrinogen-to-lymphocyte ratio after radiotherapy on survival outcomes in glioblastoma

  2023cites this paper
• Statistical characterization of the dynamics of Glioblastoma Multiforme subtypes through parameters estimation of the epigenetic landscape

  2023influential citation
• General Clinico-Pathological Characteristics in Glioblastomas in Correlation with p53 and Ki67

  2023cites this paper
• Glyphosate-induced glioblastoma cell proliferation: Unraveling the interplay of oxidative, inflammatory, proliferative, and survival signaling pathways.

  2023cites this paper
• Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers

  2023cites this paper
• Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients

  2023cites this paper
• Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations

  2023cites this paper
• The Current Landscape of Glioblastoma Biomarkers in Body Fluids

  2023cites this paper
• Pengobatan Glioblastoma Multiforme Saat Ini dan Masa Depan: Literature Review

  2023cites this paper
• Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations.

  2023cites this paper
• EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes

  2023cites this paper
• An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

  2023cites this paper
• Combined Inhibition of Hedgehog and HDAC6: In Vitro and In Vivo Studies Reveal a New Role for Lysosomal Stress in Reducing Glioblastoma Cell Viability

  2023cites this paper
• Identification and Validation of Immune Pathway Subtyping in Glioblastoma to Predict Clinical Prognosis and Immunotherapy Response in Patients

  2023cites this paper
• Photodynamic therapy for glioblastoma: A light at the end of the tunnel

  2023cites this paper
• Sex hormone receptors and glioblastoma

  2022cites this paper
• Sex hormone receptors and glioblastoma

  2022cites this paper
• The Role of Apparent Diffusion Coefficient Values in Glioblastoma: Differentiating Tumor Progression Versus Treatment-Related Changes

  2022cites this paper
• Effect of Chitosan on Alginate-Based Macroporous Hydrogels for the Capture of Glioblastoma Cancer Cells.

  2022cites this paper
• Assessment of Heat-Shock Protein Hsp70 Colocalization with Markers of Tumor Stem-Like Cells

  2022cites this paper
• Molecular and Circulating Biomarkers in Patients with Glioblastoma

  2022cites this paper
• Identification of a Five-mRNA Signature as a Novel Potential Prognostic Biomarker for Glioblastoma by Integrative Analysis

  2022cites this paper
• A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification

  2022cites this paper
• Initial preclinical evaluation of 68Ga-DOTA-(Ser)3-LTVSPWY peptide as a PET radiotracer for glioblastoma targeting and imaging

  2022cites this paper
• Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines

  2022cites this paper
• Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives

  2022cites this paper
• Association between microRNAs 10b/21/34a and acute toxicity in glioblastoma patients treated with radiotherapy and temozolomide

  2022cites this paper
• New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme

  2022cites this paper
• XIST in Brain Cancer.

  2022cites this paper
• Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

  2022cites this paper
• Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers

  2022cites this paper
• Recognition of a Novel Gene Signature for Human Glioblastoma

  2022cites this paper
• Recent advances in the therapeutic strategies of glioblastoma multiforme.

  2022cites this paper
• Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells

  2022cites this paper
• Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells.

  2022cites this paper
• Potential Therapeutic Effects of PPAR Ligands in Glioblastoma

  2022cites this paper
• Integrated Analysis to Obtain Potential Prognostic Signature in Glioblastoma

  2022cites this paper
• The hsa-miR-516a-5p and hsa-miR-516b-5p microRNAs reduce the migration and invasion on T98G glioblastoma cell line.

  2022cites this paper
• A systematic review of extracellular vesicles as non-invasive biomarkers in glioma diagnosis, prognosis, and treatment response monitoring

  2021cites this paper
• Interplay between DNA Methyltransferase 1 and Micrornas During Tumorigenesis.

  2021cites this paper
• WMLRR: A Weighted Multi-View Low Rank Representation to Identify Cancer Subtypes From Multiple Types of Omics Data

  2021cites this paper
• TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells

  2021cites this paper
• An Immune-Related Gene Pairs Signature Predicts Prognosis and Immune Heterogeneity in Glioblastoma

  2021cites this paper
• Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial

  2021cites this paper
• Diagnosis and Management of Glioblastoma: A Comprehensive Perspective

  2021cites this paper
• Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas

  2021cites this paper
• MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44

  2021cites this paper
• Chemoprevention and therapeutic role of essential oils and phenolic compounds: modeling tumor microenvironment in glioblastoma.

  2021cites this paper
• Polyphenolic Compounds of Crataegus Berry, Leaf, and Flower Extracts Affect Viability and Invasive Potential of Human Glioblastoma Cells

  2021cites this paper
• The oncogenic role of both lncRNA PANDA and BCL2 gene in glioblastoma

  2021cites this paper
• Altered expression of EGFR and miR-34a derived from serum and tumoral tissue was associated with glioblastoma multiform.

  2021cites this paper
• miR‐218 affects the ECM composition and cell biomechanical properties of glioblastoma cells

  2021cites this paper
• Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome

  2021cites this paper
• Current Development of Glioblastoma Therapeutic Agents

  2021cites this paper
• Study on the Inhibitory Effect of Curcumin on GBM and Its Potential Mechanism

  2021cites this paper
• Knockdown of carbohydrate sulfotransferase 12 decreases the proliferation and mobility of glioblastoma cells via the WNT/β-catenin pathway

  2021cites this paper
• Examining the Role of Specialized DNA Polymerases in the Development of Temozolomide Resistance in Glioblastoma Multiforme

  2021cites this paper
• Microglia-Specific Expression of HEXA and HEXB Leads to Poor Prognosis in Glioblastoma Patients

  2021cites this paper
• Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

  2021influential citation
• Small RNA Sequencing Identifies PIWI-Interacting RNAs Deregulated in Glioblastoma—piR-9491 and piR-12488 Reduce Tumor Cell Colonies In Vitro

  2021influential citation
• Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme

  2021cites this paper
• Adjusting the Clock: the Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy

  2021influential citation
• An immune-related long non-coding RNA signature predicts prognosis in glioblastoma patients

  2021cites this paper
• Circular RNA SERPINE2 promotes development of glioblastoma by regulating the miR-361-3p/miR-324-5p/BCL2 signaling pathway

  2021cites this paper
• Coexistence of “Cream Skimmer” and “Crumb Picker” Phenotypes in Nature and in Cancer

  2021cites this paper
• Integrative Analyses and Verification of the Expression and Prognostic Significance for RCN1 in Glioblastoma Multiforme

  2021cites this paper
• Formulation development of Temozolomide liposomal formulation in the treatment of Glioma

  2021cites this paper
• m6A reader IGF2BP2-stabilized CASC9 accelerates glioblastoma aerobic glycolysis by enhancing HK2 mRNA stability

  2021cites this paper
• Precision Neurosurgery: A Path Forward

  2021cites this paper
• Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling

  2021cites this paper
• Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.

  2021cites this paper